We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Speaker: Prof. Pilar Eroles Asensio. Professor in the field of Physiology. University of Valencia.
Abstract: Triple-negative breast cancer (TNBC) and ovarian cancer are among the most aggressive cancers affecting women, mainly due to their high metastatic potential, frequent therapeutic resistance, and poor clinical outcomes. The research presented focuses on developing innovative strategies to improve treatment efficacy and advance precision oncology in these challenging diseases.A major area of interest has been the development of targeted nanomedicine approaches to enhance the therapeutic efficacy of doxorubicin while minimizing systemic toxicity. These nanoparticle-based platforms not only increase drug delivery to tumors but also contribute to remodeling the tumor microenvironment, improving antitumor responses. In parallel, the identification of key microRNAs involved in chemotherapy resistance, including the miR-449 family and miR-99a-5p, has provided new insights into the molecular mechanisms driving treatment failure and revealed promising therapeutic targets for restoring drug sensitivity. Additionally, efforts have focused on the discovery of predictive biomarkers to support treatment decisions. In TNBC, epigenetic signatures showed potential for predicting response to chemotherapy. In advanced ovarian cancer, where treatment selection between primary surgery and neoadjuvant chemotherapy remains a clinical challenge, the identification of histopathological and molecular biomarkers may facilitate patient stratification and improve outcomes.
Host: Dr. Stefan Hummer. Main researcher Translational Molecular Pathology (VHIR)
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.Legal basis: Consent of the data subject.Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.Source: The data subject.Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.